SNPMiner Trials by Shray Alag


SNPMiner SNPMiner Trials (Home Page)


Report for Clinical Trial NCT02419287

Developed by Shray Alag, 2020.
SNP Clinical Trial Gene

Pilot Study of Crizotinib in Relapsed ALK+ Lymphomas

The purpose of this study is to determine the response and the duration of it in patients affected by ALK+ lymphoma that are resistant or refractory to standard cytotoxic treatment that will be treated with crizotinib.

NCT02419287 Anaplastic Large Cell Lymphoma, ALK-Positive
MeSH:Lymphoma Lymphoma, Large-Cell, Anaplastic
HPO:Anaplastic large-cell lymphoma Lymphoma

1 Interventions

Name: crizotinib

Type: Drug
Group Labels: 1

crizotinib


Primary Outcomes

Measure: objective response rates (ORR) in subjects with ALK+ lymphomas resistant or refractory to standard cytotoxic treatment, according to RECIST 1.1 criteria.

Time: the entire duration of the study (5 years)

Measure: Duration ORR

Time: the entire duration of the study (5 years)

Secondary Outcomes

Measure: Progression free survival (PFS) in ALK+ lymphoma patients treated with crizotinib, that are resistant or refractory to standard cytotoxic treatment.

Time: the entire duration of the study (5 years)

Measure: Number of patients with adverse events after crizotinib treatment

Time: the entire duration of the study (5 years)

Measure: Quality of Life (QoL) in this population of patients using the the EORTC - C30 Quality of Life questionnaire

Time: the entire duration of the study (5 years)

Measure: Overall survival (OS) in ALK+ lymphoma patients treated with crizotinib

Time: the entire duration of the study (5 years)

Purpose: Treatment

Allocation: N/A

Single Group Assignment


There is one SNP

SNPs


1 I1171N

Although crizotinib shows activity, relapses occur typically within 5 months after starting treatment and were supported by mutations like I1171N. --- I1171N ---



HPO Nodes


HPO: